Florian Schlotter, Renata C C de Freitas, Maximillian A Rogers, Mark C Blaser, Pin-Jou Wu, Hideyuki Higashi, Arda Halu, Farwah Iqbal, Allison B Andraski, Cayla N Rodia, Shiori Kuraoka, Jennifer R Wen, Michael Creager, Tan Pham, Joshua D Hutcheson, Simon C Body, Alison B Kohan, Frank M Sacks, Masanori Aikawa, Sasha A Singh, Elena Aikawa
Calcific aortic valve disease (CAVD) occurs when subpopulations of valve cells undergo specific differentiation pathways, promoting tissue fibrosis and calcification. Lipoprotein particles carry oxidized lipids that promote valvular disease, but low-density lipoprotein lowering therapies have failed in clinical trials, and there are currently no pharmacological interventions available for this disease. Apolipoproteins are known promotors of atherosclerosis, butwhether they possess pathogenic properties in CAVD is less clear...
December 17, 2020: Journal of Biological Chemistry